NCT05509153

A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Western Sydney Local Health District · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.

Conditions

• Huntington Disease

Interventions

Type	Name	Description
DRUG	NAC	1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
DRUG	Placebo	Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day

Timeline

• Start date: 2024-06-01
• Primary completion: 2026-11-01
• Completion: 2027-05-01
• First posted: 2022-08-19
• Last updated: 2025-02-28

Locations

5 sites across 1 country: Australia